Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
J Eur Acad Dermatol Venereol ; 34(9): 2051-2058, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32027420

ABSTRACT

INTRODUCTION: The National Psoriasis Foundation (NPF) published treat-to-target guidelines for psoriasis, yet their applicability in clinical practice remains unknown. OBJECTIVES: To estimate the proportion of psoriasis patients meeting the NPF's body surface area (BSA) 'target' (≤1%) and 'acceptable' (≤3%) response criteria and the cross-sectional associations of these criteria with patient-reported outcomes (PROs) in the Corrona Psoriasis Registry. METHODS: Separately for three independent cross-sectional cohorts of patients at the (i) enrolment, (ii) 6-month and (iii) 12-month visits, we calculated the proportion of patients with BSA ≤1% and ≤3%. Furthermore, we calculated odds ratios estimating the risk of PROs associated with not meeting criteria in the 6-month cohort. RESULTS: The enrolment, 6- and 12-month cohorts included 2794, 1310 and 629 patients, respectively. At enrolment, 24% of patients had a BSA ≤ 1% and 41% a BSA ≤ 3%. In the 6-month cohort, 43%/64% had a BSA ≤ 1%/BSA ≤ 3%. In the 12-month cohort, 46%/69% of patients had a BSA ≤ 1%/BSA ≤ 3%. Patients not at target/acceptable criteria had higher odds for worse quality of life compared with those who were. CONCLUSION: While most patients at 6- and 12-month visits were at the 'acceptable' response, less than half were at the 'target' response despite systemic therapy. There remain unmet needs to optimize psoriasis therapy and further validate current treat-to-target guidelines.


Subject(s)
Psoriasis , Quality of Life , Cross-Sectional Studies , Humans , Patient Reported Outcome Measures , Prevalence , Psoriasis/drug therapy , Psoriasis/epidemiology , Registries , Severity of Illness Index
3.
Br J Dermatol ; 170(3): 672-680, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24266717

ABSTRACT

BACKGROUND: Treatment satisfaction among patients with moderate-to-severe psoriasis has not been studied and compared across treatments using a validated instrument. OBJECTIVES: To assess patient-reported satisfaction with systemic and phototherapy treatments for moderate-to-severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality-of-life measures. METHODS: This was a cross-sectional study of 1182 patients with moderate-to-severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II. RESULTS: Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic-methotrexate combinations, or phototherapy (83.3); scores were lowest for those receiving topical therapies only or acitretin (66.7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7.2-8.3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8.9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = -0.36, P < 0.001) and the Dermatology Life Quality Index (ρ = -0.47, P < 0.001). CONCLUSIONS: Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.


Subject(s)
Patient Satisfaction , Psoriasis/therapy , Adult , Cross-Sectional Studies , Dermatologic Agents/therapeutic use , Female , Humans , Male , Middle Aged , Psoriasis/psychology , Quality of Life , Surveys and Questionnaires , Treatment Outcome , Ultraviolet Therapy/psychology
4.
Br J Dermatol ; 163(2): 334-9, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20545678

ABSTRACT

BACKGROUND: Data on pregnancy outcomes among women with psoriasis are lacking. However, there are several known comorbidities of psoriasis, including obesity, smoking and depression, each of which increases the risk for negative birth outcomes. OBJECTIVES: To determine if pregnant women with psoriasis have an excess of potentially modifiable risk factors for adverse pregnancy outcomes. METHODS: Prospectively collected data from the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases in Pregnancy Project were analysed to compare the prevalence of selected risk factors between 170 pregnant women with psoriasis and 158 nondiseased controls. RESULTS: Women with psoriasis were more likely to be overweight/obese prior to pregnancy (P < 0.0001), to smoke (P < 0.0001), or to have a diagnosis of depression (P = 0.03), and were less likely to have been taking preconceptional vitamin supplements (P = 0.004). After controlling for race/ethnicity and socioeconomic status, women with psoriasis were 2.37 (95% confidence interval 1.45-3.87) times more likely to be overweight/obese as women without psoriasis. Duration of disease, age at onset, measures of disease impact during pregnancy, or use of biologics in pregnancy were not significant predictors of overweight/obesity in the subset of psoriatic women. CONCLUSIONS: Pregnant women with psoriasis may be at increased risk for adverse pregnancy outcomes due to comorbidities or other health behaviours associated with the disease. These should be taken into consideration during clinical treatment of women with psoriasis who are in their childbearing years.


Subject(s)
Pregnancy Complications/epidemiology , Pregnancy Outcome , Psoriasis/epidemiology , Adult , Age Factors , Canada/epidemiology , Cohort Studies , Depression/epidemiology , Dietary Supplements/statistics & numerical data , Female , Humans , Overweight/epidemiology , Pregnancy , Prospective Studies , Risk Factors , Smoking/epidemiology , United States/epidemiology
6.
Pediatr Dermatol ; 9(3): 268-71, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1488378

ABSTRACT

Zinc deficiency, whether a result of an acquired or inherited abnormality of zinc metabolism, is associated with characteristic cutaneous findings. The inherited variety is known as acrodermatitis enteropathica. We present a case of zinc deficiency secondary to starvation induced by anorexia nervosa. Since the cutaneous stigmata of zinc deficiency and anorexia nervosa can initially be subtle and occasionally overlap, we believe that screening zinc levels in patients with anorexia nervosa with prominent cutaneous findings should be considered.


Subject(s)
Acrodermatitis/etiology , Anorexia Nervosa/complications , Facial Dermatoses/etiology , Zinc/deficiency , Acrodermatitis/metabolism , Adult , Anorexia Nervosa/metabolism , Facial Dermatoses/metabolism , Female , Humans
7.
Int J Dermatol ; 31(8): 582-7, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1428453

ABSTRACT

Adult T-cell leukemia/lymphoma (ATLL) is characterized by cutaneous disease, hypercalcemia, associated HTLV-I infection, and a fulminant course refractory to therapy. A patient with acute ATLL is described, and the natural history of ATLL is reviewed.


Subject(s)
Leukemia-Lymphoma, Adult T-Cell/complications , Skin Diseases/etiology , Diagnosis, Differential , Humans , Leukemia-Lymphoma, Adult T-Cell/diagnosis , Leukemia-Lymphoma, Adult T-Cell/mortality , Leukemia-Lymphoma, Adult T-Cell/therapy , Male , Middle Aged , Prognosis , Skin Diseases/pathology , Survival Rate
8.
Pediatr Dermatol ; 8(1): 46-50, 1991 Mar.
Article in English | MEDLINE | ID: mdl-1862025

ABSTRACT

Livedo reticularis (LR) has been associated with numerous systemic diseases. Its relationship to diabetes mellitus (DM), however, has been poorly characterized. We report a case of LR in a 17-year-old with type 1 DM.


Subject(s)
Diabetes Mellitus, Type 1/complications , Pigmentation Disorders/complications , Skin/blood supply , Adolescent , Female , Humans , Vascular Diseases/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...